Prophase Labs Stock Cash And Equivalents
| PRPH Stock | USD 0.63 0.02 3.28% |
ProPhase Labs fundamentals help investors to digest information that contributes to ProPhase Labs' financial success or failures. It also enables traders to predict the movement of ProPhase Stock. The fundamental analysis module provides a way to measure ProPhase Labs' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to ProPhase Labs stock.
ProPhase |
ProPhase Labs Company Cash And Equivalents Analysis
ProPhase Labs' Cash or Cash Equivalents are the most liquid of all assets found on the company's balance sheet. It is used in calculating many of the firm's liquidity ratios and is a good indicator of the overall financial health of a company. Companies with a lot of cash are usually attractive takeover targets. Cash Equivalents are balance sheet items that are typically reported using currency printed on notes.
Current ProPhase Labs Cash And Equivalents | 27.5 M |
Most of ProPhase Labs' fundamental indicators, such as Cash And Equivalents, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, ProPhase Labs is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Cash equivalents represent current assets that are easily convertible to cash such as short term bonds, savings account, money market funds, or certificate of deposits (CDs). One of the important consideration companies make when classifying assets as cash equivalent is that investments they report on their balance sheets under current assets should have almost no risk of change in value over the next few months (usually three months).
| Competition |
In accordance with the recently published financial statements, ProPhase Labs has 27.5 M in Cash And Equivalents. This is 96.65% lower than that of the Pharmaceuticals sector and significantly higher than that of the Health Care industry. The cash and equivalents for all United States stocks is 98.98% higher than that of the company.
ProPhase Cash And Equivalents Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses ProPhase Labs' direct or indirect competition against its Cash And Equivalents to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of ProPhase Labs could also be used in its relative valuation, which is a method of valuing ProPhase Labs by comparing valuation metrics of similar companies.ProPhase Labs is currently under evaluation in cash and equivalents category among its peers.
ProPhase Fundamentals
| Return On Equity | -0.51 | ||||
| Return On Asset | -0.23 | ||||
| Profit Margin | (1.46) % | ||||
| Operating Margin | (3.16) % | ||||
| Current Valuation | 44.13 M | ||||
| Shares Outstanding | 23.87 M | ||||
| Shares Owned By Insiders | 14.33 % | ||||
| Shares Owned By Institutions | 7.63 % | ||||
| Number Of Shares Shorted | 109.22 K | ||||
| Price To Earning | 6.59 X | ||||
| Price To Book | 0.39 X | ||||
| Price To Sales | 0.83 X | ||||
| Revenue | 44.38 M | ||||
| Gross Profit | 70.65 M | ||||
| EBITDA | (14.83 M) | ||||
| Net Income | (16.78 M) | ||||
| Cash And Equivalents | 27.5 M | ||||
| Cash Per Share | 1.72 X | ||||
| Total Debt | 21.38 M | ||||
| Debt To Equity | 0.19 % | ||||
| Current Ratio | 4.20 X | ||||
| Book Value Per Share | 2.74 X | ||||
| Cash Flow From Operations | (11.35 M) | ||||
| Short Ratio | 7.04 X | ||||
| Earnings Per Share | (1.53) X | ||||
| Target Price | 18.5 | ||||
| Number Of Employees | 113 | ||||
| Beta | -0.095 | ||||
| Market Capitalization | 14.95 M | ||||
| Total Asset | 91.93 M | ||||
| Retained Earnings | (5.03 M) | ||||
| Working Capital | 26.73 M | ||||
| Current Asset | 9.73 M | ||||
| Current Liabilities | 6.25 M | ||||
| Net Asset | 91.93 M |
About ProPhase Labs Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze ProPhase Labs's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of ProPhase Labs using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of ProPhase Labs based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Currently Active Assets on Macroaxis
When determining whether ProPhase Labs offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of ProPhase Labs' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Prophase Labs Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Prophase Labs Stock:Check out ProPhase Labs Piotroski F Score and ProPhase Labs Altman Z Score analysis. For more detail on how to invest in ProPhase Stock please use our How to Invest in ProPhase Labs guide.You can also try the Idea Optimizer module to use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio .
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of ProPhase Labs. If investors know ProPhase will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about ProPhase Labs listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.95) | Earnings Share (1.53) | Revenue Per Share 0.996 | Quarterly Revenue Growth (0.81) | Return On Assets (0.23) |
The market value of ProPhase Labs is measured differently than its book value, which is the value of ProPhase that is recorded on the company's balance sheet. Investors also form their own opinion of ProPhase Labs' value that differs from its market value or its book value, called intrinsic value, which is ProPhase Labs' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because ProPhase Labs' market value can be influenced by many factors that don't directly affect ProPhase Labs' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between ProPhase Labs' value and its price as these two are different measures arrived at by different means. Investors typically determine if ProPhase Labs is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, ProPhase Labs' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.